OncoMatch/Clinical Trials/NCT06476808
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Is NCT06476808 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies BMS-986463 for high-grade serous ovarian carcinoma (hgsoc).
Treatment: BMS-986463 — The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- Valkyrie Clinical Trials · Los Angeles, California
- John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, New Jersey
- Local Institution - 0045 · Columbus, Ohio
- Local Institution - 0046 · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06476808 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify